• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

CONCEPTT Study: Time for Continuous Glucose Monitoring for All Pregnant Women with Type 1 Diabetes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  1. Continuous glucose monitoring (CGM) provides contemporaneous glucose readings, thus allowing patients to adjust insulin in real-time
  2. Data in non-pregnant women show benefit but conflicting data in pregnancy
  3. Feig et al. (Lancet, 2017) determined the effectiveness of continuous glucose monitoring (CGM) on maternal glucose control compared to capillary glucose monitoring alone

METHODS:

  • Multicenter, open-label, randomized controlled trial (2013-2016)
  • 31 hospital centers in Canada, England, Scotland, Spain, Italy, Ireland, and the USA
  • Women aged 18 to 40 years, with type 1 diabetes for a minimum of 1 year, receiving intensive insulin therapy, and pregnant or planning pregnancy
    • Live singleton fetus confirmed by ultrasound
    • ≤13 weeks and 6 days’ gestation
    • Pregnant: HbA1c between 6.5–10.0% (48–86 mmol/mol)
    • Planning for pregnancy: 7.0–10.0% (53–86 mmol/mol)
  • Ran 2 trials in parallel for (1) pregnant and (2) planning pregnancy
  • In both trials, participants were assigned to the following cohorts
    • Receive CGM in addition to capillary glucose monitoring
    • Receive capillary glucose monitoring
  • Randomization was stratified by insulin delivery and baseline HbA1c
  • Primary outcome was change in HbA1c
    • at 34 weeks’ gestation in pregnant participants
    • at 24 weeks for planning pregnancy participants
  • Secondary outcomes included obstetric and neonatal health outcomes

RESULTS:

  • 325 women were randomized
  • When comparing pregnant CGM users to capillary monitored group, CGM users
    • had a slightly greater change in HbA1c (mean difference -0.19%; 95% CI -0.34 to -0.03; p=0.0207)
    • Spent more time in target range (68% vs 61%; 0.0034)
    • Spent less time hyperglycemic range (27% vs 32%; p= 0.0279)
    • Had comparable hypoglycemic episodes
    • Spent comparable amount of time in hypoglycemic range (3% vs 4%, respectively)
  • Neonatal outcomes in CGM users were significantly improved
    • Lower incidence of large for gestational age (odds ratio [OR] 0.51, 95% CI 0.28 – 0.90; p=0.0210)
    • Fewer NICU admissions lasting more than 24 h (OR 0.48; 95% CI 0.26 – 0.86; p=0.0157)
    • Fewer incidences of neonatal hypoglycemia (OR 0.45; 95% CI 0.22 to 0.89; p=0.0250)
    • 1-day shorter length of hospital stay (p=0.0091)
  • There was no apparent benefit of CGM for women planning pregnancy
  • CGM users had significantly more adverse skin reactions during trials (48% CGM vs 8% control during pregnancy; 44% CGM vs 9% control planning pregnancy)
  • Data was generalizable across centers

CONCLUSION:

  • CGM during pregnancy in patients with type 1 diabetes is linked to improved neonatal outcomes, likely because of better maternal glycemic control and reduced maternal hyperglycemia
  • Number needed to treat (NNT) with CGM
    • 6 pregnant women NNT to prevent one NICU admission
    • 6 pregnant women NNT to prevent one large for gestational age
    • 8 pregnant women NNT to prevent one case of neonatal hypoglycemia
  • The authors conclude that guidelines in type 1 diabetes in pregnancy should be revised to recommend offering CGM to pregnant women with type 1 diabetes using intensive insulin therapy in the first trimester

Learn More – Primary Sources:

Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Updated ACOG Guidance on Gestational Diabetes
Practical obstetrics info for your women's healthcare practice
Gestational Diabetes Mellitus – Definitions, Risk Factors and Complications
Practical obstetrics info for your women's healthcare practice
What Is The ‘One-Step’ GDM Screening Approach?
Practical obstetrics info for your women's healthcare practice
Screening for Gestational Diabetes: The ‘2 Step’ Approach

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site